Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.
Sci Rep
; 8(1): 6483, 2018 04 24.
Article
in En
| MEDLINE
| ID: mdl-29691437
ABSTRACT
The significant public health problem of Hepatitis C virus (HCV) has been partially addressed with the advent of directly acting antiviral agents (DAAs). However, the development of an effective preventative vaccine would have a significant impact on HCV incidence and would represent a major advance towards controlling and possibly eradicating HCV globally. We previously reported a genotype 1a HCV viral-like particle (VLP) vaccine that produced neutralizing antibodies (NAb) and T cell responses to HCV. To advance this approach, we produced a quadrivalent genotype 1a/1b/2a/3a HCV VLP vaccine to produce broader immune responses. We show that this quadrivalent vaccine produces antibody and NAb responses together with strong T and B cell responses in vaccinated mice. Moreover, selective neutralizing human monoclonal antibodies (HuMAbs) targeting conserved antigenic domain B and D epitopes of the E2 protein bound strongly to the HCV VLPs, suggesting that these critical epitopes are expressed on the surface of the particles. Our findings demonstrate that a quadrivalent HCV VLP based vaccine induces broad humoral and cellular immune responses that will be necessary for protection against HCV. Such a vaccine could provide a substantial addition to highly active antiviral drugs in eliminating HCV.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Viral Hepatitis Vaccines
/
Hepatitis C
/
Hepacivirus
Limits:
Animals
Language:
En
Journal:
Sci Rep
Year:
2018
Document type:
Article
Affiliation country:
Australia